Last Price
26.41
Today's Change
+0.06 (0.22%)
Day's Change
25.68 - 26.96
Trading Volume
436,967
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Andrew Cheng M.D., Ph.D. Dr. Andrew Cheng M.D., Ph.D.
Full Time Employees: 61 61
IPO Date: 2019-06-20 2019-06-20
CIK: 0001744659 0001744659
ISIN: US00973Y1082 US00973Y1082
CUSIP: 00973Y108 00973Y108
Beta: -0.26 -0.26
Last Dividend: 0.00 0.00
Dcf Diff: 22.45 22.45
Dcf: 3.96 3.96
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.